ABBV-295 vs cagrilintide/semaglutide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: Amylin receptor · full Obesity pipeline

ABBV-295

Developed by AbbVie under a licence from Gubra

Phase 2 in Obesitypeptide
Weak signal

NCT06144684 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Safety - Adverse Events (AE) incidence" (with 2 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: December 2026 · NCT07514260 (registry estimate)

Reported efficacy

Safety - Adverse Events (AE) incidence (from baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C); Safety - changes in vital signs (from baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C); Safety - Safety laboratory parameters (From baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C): Two-part first-in-human phase 1 study of subcutaneous ABBV-295, a long-acting amylin analog: ABBV-295 demonstrated a favorable tolerability profile at all evaluated dose levels and no serious adverse events were reported. Treatment showed clinically meaningful body weight reduction from -7.75% to -9.79% (least-squares mean) at week 12 with weekly dosing. (not_applicable)

Result source: NCT06144684

cagrilintide/semaglutide · CagriSema

Developed by Novo Nordisk

Phase 3 in Obesitypeptide
Reliable signal

NCT05394519 · Phase 3 · completed

This was a large, randomized, quadruple-blind, placebo-controlled trial in 1,200 patients using percentage body weight change, the standard efficacy measure for obesity treatment. CagriSema reduced body weight by 13.7% versus 3.4% on placebo, a 10.4-percentage-point difference (p<0.001), meeting the primary endpoint.

Next expected readout: March 2027 · NCT07011667 (registry estimate)

Reported efficacy

Relative change in body weight (From baseline (week 0) to end of treatment (week 68)); Achievement of greater than or equal to (≥) 5% weight reduction (From baseline (week 0) to end of treatment (week 68)): Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001) (met)

Result source: NCT05394519

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointABBV-295cagrilintide/​semaglutide
Body weight, % change—Not reported-13.7% vs -3.4%a−10.3 vs placebowk 68NCT05394519
1 other result
  • -18.4% vs -11.9% wk 68 · Phase 3 · primary NCT05813925
Weight loss of 5% or more—Not reported—Not posted · NCT05996848
Weight loss of 10% or more—Not reported—Not posted · NCT05996848
Waist circumference, change (cm)—Not reported—Not posted · NCT05996848

Body weight, % change

ABBV-295
—Not reported
cagrilintide/​semaglutide
-13.7% vs -3.4%a−10.3 vs placebowk 68NCT05394519
1 other result
  • -18.4% vs -11.9% wk 68 · Phase 3 · primary NCT05813925

Weight loss of 5% or more

ABBV-295
—Not reported
cagrilintide/​semaglutide
—Not posted · NCT05996848

Weight loss of 10% or more

ABBV-295
—Not reported
cagrilintide/​semaglutide
—Not posted · NCT05996848

Waist circumference, change (cm)

ABBV-295
—Not reported
cagrilintide/​semaglutide
—Not posted · NCT05996848
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ABBV-295: no structured comparison results are available for Obesity.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

cagrilintide/semaglutide

Weight -13.7% vs -3.4% placebo @ 68wk
percent change · % of baseline
NCT05394519 · Phase 3 · sponsor-reported, not registry data
show 1 more result
-18.4% vs -11.9% semaglutide alone @ 68wk
NCT05813925 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABBV-295's landscape · cagrilintide/semaglutide's landscape